UBS analyst Michael Leuchten downgraded Merck KGaA to Neutral from Buy saying the stock’s valuation is now close to his sum-of-the parts analysis. The analyst believes near-term catalysts are now priced into the shares. He lowered his price target for Merck KGaA to EUR 108 from EUR 115.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.